Semler Scientific (OTCMKTS:SMLR) received a $40.00 target price from analysts at Lake Street Capital in a research note issued to investors on Monday. The brokerage presently has a “buy” rating on the medical equipment provider’s stock. Lake Street Capital’s price target would suggest a potential upside of 23.08% from the stock’s current price.
Separately, Dougherty & Co initiated coverage on shares of Semler Scientific in a report on Friday, October 5th. They issued a “buy” rating and a $48.00 target price on the stock.
Shares of SMLR stock opened at $32.50 on Monday. The company has a current ratio of 0.80, a quick ratio of 0.80 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $198.93 million, a PE ratio of -116.07, a PEG ratio of 2.33 and a beta of 0.68. Semler Scientific has a 52-week low of $5.81 and a 52-week high of $40.00.
In other Semler Scientific news, VP Daniel E. Conger sold 5,000 shares of the stock in a transaction dated Thursday, September 6th. The shares were sold at an average price of $25.78, for a total value of $128,900.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 13.90% of the stock is currently owned by corporate insiders.
Semler Scientific Company Profile
Semler Scientific, Inc develops, manufactures, and markets patented products that assist healthcare providers to evaluate and treat patients with chronic diseases in the United States. Its products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition; and WellChec, a multi-test service platform to evaluate patients with various chronic diseases.
Recommended Story: How are Outstanding Shares Different from Authorized Shares?
Receive News & Ratings for Semler Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Semler Scientific and related companies with MarketBeat.com's FREE daily email newsletter.